Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$53.83 USD
-0.03 (-0.06%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $53.80 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTGX 53.83 -0.03(-0.06%)
Will PTGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Other News for PTGX
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Insider Sell: PATEL DINESH V PH D Sells Shares of Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc (PTGX) Submits NDA for Icotrokinra to FDA | PTGX stock news
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra